Viewing Study NCT07219459

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2026-01-19 @ 11:00 AM
Study NCT ID: NCT07219459
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-10-21
First Post: 2025-10-20
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Sponsor: CatalYm GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable or Metastatic Hepatocellular Carcinoma View
None Failure of First-Line Treatment That Included an Anti PD-(L)1 Compound View
None Child-Pugh A Hepatocellular Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CTL-002 View
None Visugromab View
None GDF-15 View